Bioxcel therapeutics to participate at two upcoming investor conferences

New haven, conn., june 07, 2022 (globe newswire) -- bioxcel therapeutics, inc. (nasdaq: btai), a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced that vimal mehta, ph.d., founder and chief executive officer, will participate in fireside chats at two upcoming investor conferences. dr. mehta will discuss the company's neuroscience and immuno-oncology programs as well as its artificial intelligence platform used to augment and accelerate the drug candidate discovery and development process. he will also discuss the company's commercial and launch readiness plans for igalmi™ (dexmedetomidine) sublingual film.
BTAI Ratings Summary
BTAI Quant Ranking